Men (aged 40-49 years) with a single baseline prostate-specific antigen below 1.0 ng/mL have a very low long-term risk of prostate cancer: Results from a prospectively screened population cohort

Christopher J. Weight, Simon P. Kim, Debra J. Jacobson, Michaela E. McGree, Robert Jeffrey Karnes, Jennifer St. Sauver

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objective To study the use of a baseline prostate-specific antigen (PSA) and digital rectal examination in men (aged 40-49 years) in predicting long-term prostate cancer risk in a prospectively followed, representative population cohort. Patients and Methods Since 1990, a random sample of men in Olmsted County (aged 40-49 years) has been followed up prospectively (n = 268), with biennial visits, including a urologic questionnaire, PSA screening, and physical examination. The ensuing risk of prostate cancer (CaP) was compared using survival analyses. Results Median follow-up was 16.3 years (interquartile range 14.0-17.3, max 19.1). For men with a baseline PSA <1.0 ng/mL (n = 195), the risk of subsequent Gleason 6 CaP diagnosis by 55 years was 0.6% (95% confidence interval [CI] 0%-1.7%) and 15.7% (95% CI 6.5%-24.9%) for men with a baseline PSA ≥1.0 ng/mL. No man with a low baseline PSA developed an intermediate or high risk CaP, whereas 2.6% of men with a higher baseline PSA did (95% CI 0.58%-4.6%). Conclusion Men (aged 40-49 years) can be stratified with a baseline PSA. If it is below 1.0 ng/mL, there is very little risk for developing a lethal CaP, and as many as 75% of men might be able to avoid additional PSA screening until 55 years. Conversely, men aged 40-49 years with a baseline PSA level >1.0 ng/mL had a significant risk of CaP diagnosis and should be monitored more closely.

Original languageEnglish (US)
Pages (from-to)1211-1217
Number of pages7
JournalUrology
Volume82
Issue number6
DOIs
StatePublished - Dec 2013

Fingerprint

Prostate-Specific Antigen
Prostatic Neoplasms
Population
Digital Rectal Examination
Survival Analysis
Physical Examination

ASJC Scopus subject areas

  • Urology

Cite this

Men (aged 40-49 years) with a single baseline prostate-specific antigen below 1.0 ng/mL have a very low long-term risk of prostate cancer : Results from a prospectively screened population cohort. / Weight, Christopher J.; Kim, Simon P.; Jacobson, Debra J.; McGree, Michaela E.; Karnes, Robert Jeffrey; St. Sauver, Jennifer.

In: Urology, Vol. 82, No. 6, 12.2013, p. 1211-1217.

Research output: Contribution to journalArticle

@article{d7bc74a3377f465ea4cd6540ae91eeae,
title = "Men (aged 40-49 years) with a single baseline prostate-specific antigen below 1.0 ng/mL have a very low long-term risk of prostate cancer: Results from a prospectively screened population cohort",
abstract = "Objective To study the use of a baseline prostate-specific antigen (PSA) and digital rectal examination in men (aged 40-49 years) in predicting long-term prostate cancer risk in a prospectively followed, representative population cohort. Patients and Methods Since 1990, a random sample of men in Olmsted County (aged 40-49 years) has been followed up prospectively (n = 268), with biennial visits, including a urologic questionnaire, PSA screening, and physical examination. The ensuing risk of prostate cancer (CaP) was compared using survival analyses. Results Median follow-up was 16.3 years (interquartile range 14.0-17.3, max 19.1). For men with a baseline PSA <1.0 ng/mL (n = 195), the risk of subsequent Gleason 6 CaP diagnosis by 55 years was 0.6{\%} (95{\%} confidence interval [CI] 0{\%}-1.7{\%}) and 15.7{\%} (95{\%} CI 6.5{\%}-24.9{\%}) for men with a baseline PSA ≥1.0 ng/mL. No man with a low baseline PSA developed an intermediate or high risk CaP, whereas 2.6{\%} of men with a higher baseline PSA did (95{\%} CI 0.58{\%}-4.6{\%}). Conclusion Men (aged 40-49 years) can be stratified with a baseline PSA. If it is below 1.0 ng/mL, there is very little risk for developing a lethal CaP, and as many as 75{\%} of men might be able to avoid additional PSA screening until 55 years. Conversely, men aged 40-49 years with a baseline PSA level >1.0 ng/mL had a significant risk of CaP diagnosis and should be monitored more closely.",
author = "Weight, {Christopher J.} and Kim, {Simon P.} and Jacobson, {Debra J.} and McGree, {Michaela E.} and Karnes, {Robert Jeffrey} and {St. Sauver}, Jennifer",
year = "2013",
month = "12",
doi = "10.1016/j.urology.2013.06.074",
language = "English (US)",
volume = "82",
pages = "1211--1217",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Men (aged 40-49 years) with a single baseline prostate-specific antigen below 1.0 ng/mL have a very low long-term risk of prostate cancer

T2 - Results from a prospectively screened population cohort

AU - Weight, Christopher J.

AU - Kim, Simon P.

AU - Jacobson, Debra J.

AU - McGree, Michaela E.

AU - Karnes, Robert Jeffrey

AU - St. Sauver, Jennifer

PY - 2013/12

Y1 - 2013/12

N2 - Objective To study the use of a baseline prostate-specific antigen (PSA) and digital rectal examination in men (aged 40-49 years) in predicting long-term prostate cancer risk in a prospectively followed, representative population cohort. Patients and Methods Since 1990, a random sample of men in Olmsted County (aged 40-49 years) has been followed up prospectively (n = 268), with biennial visits, including a urologic questionnaire, PSA screening, and physical examination. The ensuing risk of prostate cancer (CaP) was compared using survival analyses. Results Median follow-up was 16.3 years (interquartile range 14.0-17.3, max 19.1). For men with a baseline PSA <1.0 ng/mL (n = 195), the risk of subsequent Gleason 6 CaP diagnosis by 55 years was 0.6% (95% confidence interval [CI] 0%-1.7%) and 15.7% (95% CI 6.5%-24.9%) for men with a baseline PSA ≥1.0 ng/mL. No man with a low baseline PSA developed an intermediate or high risk CaP, whereas 2.6% of men with a higher baseline PSA did (95% CI 0.58%-4.6%). Conclusion Men (aged 40-49 years) can be stratified with a baseline PSA. If it is below 1.0 ng/mL, there is very little risk for developing a lethal CaP, and as many as 75% of men might be able to avoid additional PSA screening until 55 years. Conversely, men aged 40-49 years with a baseline PSA level >1.0 ng/mL had a significant risk of CaP diagnosis and should be monitored more closely.

AB - Objective To study the use of a baseline prostate-specific antigen (PSA) and digital rectal examination in men (aged 40-49 years) in predicting long-term prostate cancer risk in a prospectively followed, representative population cohort. Patients and Methods Since 1990, a random sample of men in Olmsted County (aged 40-49 years) has been followed up prospectively (n = 268), with biennial visits, including a urologic questionnaire, PSA screening, and physical examination. The ensuing risk of prostate cancer (CaP) was compared using survival analyses. Results Median follow-up was 16.3 years (interquartile range 14.0-17.3, max 19.1). For men with a baseline PSA <1.0 ng/mL (n = 195), the risk of subsequent Gleason 6 CaP diagnosis by 55 years was 0.6% (95% confidence interval [CI] 0%-1.7%) and 15.7% (95% CI 6.5%-24.9%) for men with a baseline PSA ≥1.0 ng/mL. No man with a low baseline PSA developed an intermediate or high risk CaP, whereas 2.6% of men with a higher baseline PSA did (95% CI 0.58%-4.6%). Conclusion Men (aged 40-49 years) can be stratified with a baseline PSA. If it is below 1.0 ng/mL, there is very little risk for developing a lethal CaP, and as many as 75% of men might be able to avoid additional PSA screening until 55 years. Conversely, men aged 40-49 years with a baseline PSA level >1.0 ng/mL had a significant risk of CaP diagnosis and should be monitored more closely.

UR - http://www.scopus.com/inward/record.url?scp=84888643698&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888643698&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2013.06.074

DO - 10.1016/j.urology.2013.06.074

M3 - Article

C2 - 24149110

AN - SCOPUS:84888643698

VL - 82

SP - 1211

EP - 1217

JO - Urology

JF - Urology

SN - 0090-4295

IS - 6

ER -